Chris Garabedian, the chief executive who turned Cambridge, Mass.-based Sarepta Therapeutics from a floundering antiviral company called AVI Biopharma into an investor darling, resigned today, according to a press release from the company. Garabedian’s relationships with both investors and, more problematically, the Food and Drug Administration had become tense as he pushed to file with the agency for approval for Sarepta’s lead drug, eteplirsen for Duchenne muscular dystrophy but had trouble communicating and sticking to timelines.
Hey, check out all the research scientist jobs. Post your resume today!
